{"id":"NCT02519855","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)","officialTitle":"A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-11","primaryCompletion":"2016-01-26","completion":"2016-01-26","firstPosted":"2015-08-11","resultsPosted":"2017-02-14","lastUpdate":"2018-10-30"},"enrollment":882,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"ZOSTAVAX™","otherNames":["V211"]},{"type":"BIOLOGICAL","name":"Placebo to ZOSTAVAX™","otherNames":[]},{"type":"BIOLOGICAL","name":"Influenza Vaccine","otherNames":["Fluzone, Vaxigrip"]}],"arms":[{"label":"Concomitant Vaccination","type":"EXPERIMENTAL"},{"label":"Nonconcomitant Vaccination","type":"EXPERIMENTAL"}],"summary":"The study evaluated immunogenicity, safety, and tolerability of ZOSTAVAX™ Vaccine (V211) administered concomitantly versus nonconcomitantly with Quadrivalent Influenza Virus vaccine (inactivated) in participants ≥50 years of age. The primary hypotheses tested 1) the noninferiority of concomitant versus nonconcomitant vaccination with regard to Varicella zoster virus (VZV) Geometric Mean Titer (GMT) antibody responses, 2) the acceptability of geometric mean fold rise in VZV antibody response after concomitant vaccination, and 3) the noninferiority of concomitant versus nonconcomitant vaccination with regard to influenza virus strain-specific GMT antibody responses.","primaryOutcome":{"measure":"Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody","timeFrame":"Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)","effectByArm":[{"arm":"Concomitant Vaccination","deltaMin":206,"sd":null},{"arm":"Nonconcomitant Vaccination","deltaMin":230.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28830693"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":435},"commonTop":["Injection site pain","Injection site erythema","Injection site swelling","Injection site pruritus"]}}